Molecular Pathology
Amirhossein Jafarian; Masoumeh Jafaripour; Masoumeh Gharib; Maryam Salehi; Nema Mohamadian Roshan; Sare Etemad; Khatoone Mirshekar; Maryam Sheikhi; Masoumeh Heidari; Behnaz Ahmadian; Zahra Khoshnegah; Hossein Ayatollahi; Payam Siyadat
Abstract
Background & Objective: Epithelial ovarian cancer (EOC) is the most prevalent type of ovarian cancer. Previous studies have elucidated different pathways for the progress of this malignancy. The mutation in the B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene, a member of the MAPK/ERK signaling ...
Read More
Background & Objective: Epithelial ovarian cancer (EOC) is the most prevalent type of ovarian cancer. Previous studies have elucidated different pathways for the progress of this malignancy. The mutation in the B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene, a member of the MAPK/ERK signaling pathway, plays a role in EOC. The current study aimed to determine the frequency of the BRAF V600E mutation in ovarian serous and mucinous tumors, including borderline and carcinoma subtypes.Methods: A total of 57 formalin-fixed paraffin-embedded samples, including serous borderline tumors (SBTs), low-grade serous carcinomas (LGSCs), high-grade serous carcinomas (HGSCs), mucinous borderline tumors (MBTs), and mucinous carcinomas, and 57 normal ovarian tissues were collected. The BRAF V600E mutation was analyzed using polymerase chain reaction (PCR) and sequencing.Results: While 40% of the SBT harbor BRAF mutation, we found no BRAF mutation in the invasive serous carcinoma (P=0.017). Also, there was only 1 BRAF mutation in MBT and no mutation in mucinous carcinomas. In addition, we found no mutation in the control group.Conclusion: The BRAF mutation is most frequent in borderline tumors but not in invasive serous carcinomas. It seems that 2 different pathways exist for the development of ovarian epithelial neoplasms: one for borderline tumors and the other for high-grade invasive carcinomas. Our study supports this hypothesis. The BRAF mutation is rare in mucinous neoplasms.
Ghodsie Alavi; Nourieh Sharifi; Ali Sadeghian; Alireza Rezaei; Hossein Shidaee
Volume 7, Issue 3 , July 2012, , Pages 151-156
Abstract
Background and Aims: Ovarian cancer is one of most common causes of cancer related women's mortalities. Human papilloma virus is a known factor concerning cervical cancer but its role in causing ovarian cancer is not yet verified. A few studies also identified HPV DNA in ovarian carcinoma tissues. However, ...
Read More
Background and Aims: Ovarian cancer is one of most common causes of cancer related women's mortalities. Human papilloma virus is a known factor concerning cervical cancer but its role in causing ovarian cancer is not yet verified. A few studies also identified HPV DNA in ovarian carcinoma tissues. However, some studies did not detect HPV DNA in ovarian carcinoma tissues. In this article, we investigated the potential role of high risk HPVs in the ovarian epithelial carcinoma.
Methods: Fifty archived epithelial ovarian cancer paraffin blocks were collected. Then, 30 non-malignant ovarian blocks used as control. These samples were histopathologically were confirmed by a pathologist and the proper blocks for DNA extraction and PCR were sorted. PCR was conducted deploying highly specific primers for high-risk types of HPV (18 and 16) according to the instructions of manufacturer company.
Results: High-risk oncogenic sequences were identified in 4 (5%) of the 80 studied samples. Of the 4 HPV positive cases, there was 1 case with normal tissue, 1 case of mucinous cyst adenocarcinoma, and 2 cases of serous cyst adenocarcinoma
Conclusion: Surprisingly, our findings could not support any association between high-risk oncogenic human papilloma virus (18 and 16) and malignant ovarian epithelial cancer. Therefore, that HPV is highly unlikely to play any causal role in the pathogenesis of epithelial ovarian neoplasia.